Drug Shortage Report for MAGNESIUM SULFATE INJECTION, USP
Report ID | 159333 |
Drug Identification Number | 02139499 |
Brand name | MAGNESIUM SULFATE INJECTION |
Common or Proper name | Magnesium Sulfate Injection |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | MAGNESIUM SULFATE |
Strength(s) | 500MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
Packaging size | 10mL |
ATC code | B05XA |
ATC description | I.V. SOLUTION ADDITIVES |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2022-05-01 |
Actual start date | 2022-05-01 |
Estimated end date | 2022-12-16 |
Actual end date | 2022-12-05 |
Shortage status | Resolved |
Updated date | 2023-01-20 |
Company comments | Fresenius Kabi Canada regrets to advise that due to production delays we will be encountering a supply interruption on our Magnesium Sulfate Injection, USP 500 mg/mL SD Vial 10 mL effective May 1, 2022 until December 16, 2022. Effective May 1, 2022 allocations of 50mL will be increased to cover 100% of 50mL demand plus 200% of 10mL demand on a mL:mL basis |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v13 | 2023-01-20 | English | Compare |
v12 | 2022-12-06 | English | Compare |
v11 | 2022-12-05 | French | Compare |
v10 | 2022-12-05 | English | Compare |
v9 | 2022-10-19 | French | Compare |
v8 | 2022-10-19 | English | Compare |
v7 | 2022-08-25 | English | Compare |
v6 | 2022-07-07 | French | Compare |
v5 | 2022-07-07 | English | Compare |
v4 | 2022-07-07 | English | Compare |
v3 | 2022-05-02 | English | Compare |
v2 | 2022-04-22 | French | Compare |
v1 | 2022-04-22 | English | Compare |
Showing 1 to 13 of 13